Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
Go back to Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist| AmerElite Solutions, Inc. New (NASDAQ: AMRX) | Delayed: 17.23 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.23 | 52 Week High | $0.19 | |||
| Open | $17.23 | 52 Week Low | $0.07 | |||
| Day High | $17.23 | P/E | N/A | |||
| Day Low | $17.23 | EPS | $-0.01 | |||
| Volume | 538 | |||||
